Immune booster shows promise for Hard-to-Treat HIV patients
NCT ID NCT00113282
First seen Apr 08, 2026 · Last updated May 16, 2026 · Updated 6 times
Summary
This study looked at whether adding a drug called Interleukin-2 (IL-2) to standard HIV treatment could help patients whose current therapy was failing and who had very low CD4 counts (below 200). The goal was to see if more patients could raise their CD4 counts above 200 after 52 weeks. The study involved 57 adults with HIV-1 who had tried multiple drug classes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hôpital Necker service des Maladies Infectieuses
Paris, 75015, France
Conditions
Explore the condition pages connected to this study.